Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
/PRNewswire/ -- Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibody and antibody drug conjugate (ADC)...
Source: prnewswire.com